PCYC-1104-CA: Multicenter, Phase II Study of Bruton’s Tyrosine Kinase Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
To access the most up-to-date information on this study,
please refer to this page at ClinicalTrials.gov.
Multicenter, Phase II study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
The purpose of this study is to establish the safety and efficacy of PCI-32765 in subjects with relapsed/refractory mantle cell lymphoma (MCL).